

## REMARKS

*Claim rejections:*


Claims 1-15 are pending. The Examiner has rejected Claim 7 and 8 under 35 U.S.C. 112, second paragraph. Claim 7 has been amended to recite an acceptable carrier as per the Examiner's suggestion. Claim 8 depends from Claim 7. This amendment is believed to overcome the rejection under 35 U.S.C. 112, second paragraph.

The Examiner has rejected Claims 1-15 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims of copending Application Nos. 10/410,601 and 10/410,892. The compounds claimed in these copending applications have a -COOH group attached to the right phenyl ring of the molecule. Claims 1, 2, 5, 14 and 15 have been amended to delete "COOH" from the definition of A in the instant application. Please note that this COOH moiety mistakenly appears in two places for each definition of A. According, it has been deleted in both places where it appeared. The remaining rejected claims of the instant application depend from the amended claims. Applicants submit that this amendment is sufficient to overcome the double patenting rejection of Claims 1-15.

## Conclusion

Applicants submit that the instant application is now in condition for allowance.

Respectfully submitted,



Barbara E. Kurys, Reg. No. 34,650  
Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807-0800  
Telephone (908) 231-2965  
Telefax (908) 231-2626

Aventis Docket No. DEAV2002/0050